PID
MCID: PLV003
MIFTS: 55

Pelvic Inflammatory Disease (PID)

Categories: Infectious diseases, Nephrological diseases, Reproductive diseases

Aliases & Classifications for Pelvic Inflammatory Disease

MalaCards integrated aliases for Pelvic Inflammatory Disease:

Name: Pelvic Inflammatory Disease 12 74 54 42 3 44 15 17 71
Pid 12 3

Classifications:



External Ids:

Disease Ontology 12 DOID:1003
ICD9CM 34 614.9
MeSH 44 D000292
NCIt 50 C3889
SNOMED-CT 67 266648001
ICD10 32 N73.9
UMLS 71 C0242172

Summaries for Pelvic Inflammatory Disease

MedlinePlus : 42 Pelvic inflammatory disease (PID) is an infection and inflammation of the uterus, ovaries, and other female reproductive organs. It causes scarring in these organs. This can lead to infertility, ectopic pregnancy, pelvic pain, abscesses, and other serious problems. PID is the most common preventable cause of infertility in the United States. Gonorrhea and chlamydia, two sexually transmitted diseases, are the most common causes of PID. Other bacteria can also cause it. You are at greater risk if you Are sexually active and younger than 25 Have more than one sex partner Douche Some women have no symptoms. Others have pain in the lower abdomen, fever, smelly vaginal discharge, irregular bleeding, and pain during intercourse or urination. Doctors diagnose PID with a physical exam, lab tests, and imaging tests. Antibiotics can cure PID. Early treatment is important. Waiting too long increases the risk of infertility.

MalaCards based summary : Pelvic Inflammatory Disease, also known as pid, is related to salpingitis and peritonitis, and has symptoms including fever, pruritus and pelvic pain. An important gene associated with Pelvic Inflammatory Disease is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Moxifloxacin and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include uterus, breast and ovary, and related phenotypes are cardiovascular system and immune system

Disease Ontology : 12 A female reproductive system disease that is characterized by an infection of the female reproductive organs.

CDC : 3 Untreated sexually transmitted diseases (STDs) can cause pelvic inflammatory disease (PID), a serious condition, in women. 1 in 8 women with a history of PID experience difficulties getting pregnant. You can prevent PID if you know how to protect yourself.

Wikipedia : 74 Pelvic inflammatory disease, also known as pelvic inflammatory disorder (PID), is an infection of the... more...

Related Diseases for Pelvic Inflammatory Disease

Diseases related to Pelvic Inflammatory Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 495)
# Related Disease Score Top Affiliating Genes
1 salpingitis 32.2 TLR2 HSPD1 CRP
2 peritonitis 32.1 TLR4 TLR2 MPO CRP CCL2
3 chlamydia 31.9 TLR4 TLR2 IFNG HSPD1 CRP CCL2
4 cervicitis 31.1 TLR4 IL2 HSPD1
5 appendicitis 30.8 TLR4 MPO MMP9 IL2 IFNG CRP
6 urethritis 30.6 TLR4 TLR2 HSPD1 CRP
7 urinary tract infection 30.4 TLR4 LCN2 CRP
8 exanthem 30.4 IL2 IFNG CRP
9 candidiasis 30.3 TLR4 TLR2 IL2 IFNG
10 adenomyosis 30.3 MMP9 MMP2 CDH1
11 proctitis 30.2 MPO LCN2 CRP
12 vulvovaginal candidiasis 30.2 TLR2 LCN2 IL2
13 toxic shock syndrome 30.2 TLR4 TLR2 IL2 IFNG HSPD1 CRP
14 familial mediterranean fever 30.2 TLR4 TLR2 CRP
15 vaginal disease 30.2 TLR4 TLR2 IL2 CRP
16 diarrhea 30.1 TLR4 MPO IL2 IL13 IFNG CDH1
17 secondary progressive multiple sclerosis 30.1 MMP9 IFNG CCL2
18 myocarditis 30.1 TLR4 IL2 IFNG CCL2
19 gastroenteritis 30.1 MMP9 IFNG CRP CDH1
20 cystitis 30.0 TLR4 IL2 CST3 CRP CDH1 CCL2
21 nocardiosis 30.0 IFNG HSPD1 CRP
22 disease by infectious agent 30.0 TLR4 TLR2 IL2 IFNG HSPD1 CRP
23 keratoconjunctivitis 30.0 MMP9 IL2 IL13 IFNG CCL2
24 extrapulmonary tuberculosis 30.0 TLR2 TIRAP IFNG CRP CCL2
25 acute cystitis 30.0 TLR4 LCN2 CST3 CRP CCL2
26 neutropenia 29.9 TLR4 MPO IL2 IFNG CRP
27 severe acute respiratory syndrome 29.9 TLR4 IFNG CTSB CRP CCL2
28 chronic fatigue syndrome 29.9 TLR4 IL2 IL13 IFNG
29 hyper ige syndrome 29.9 TLR4 TLR2 MMP9 IL13 IFNG
30 conjunctivitis 29.9 MPO MMP9 IL2 IL13 IFNG CCL2
31 chlamydia pneumonia 29.8 TLR4 TLR2 HSPD1 CRP CCL2
32 pyelonephritis 29.8 TLR4 MMP9 LCN2 IFNG CRP CCL2
33 skin disease 29.8 TLR2 MPO IL2 IL13 IFNG CRP
34 immune deficiency disease 29.8 TLR2 IL2 IL13 IFNG HSPD1 CXCL12
35 mycobacterium tuberculosis 1 29.8 TLR4 TLR2 TLR1 IFNG HSPD1
36 brucellosis 29.8 TLR4 MPO IL2 IL13 IFNG CRP
37 proteasome-associated autoinflammatory syndrome 1 29.6 TLR4 TLR2 MPO MMP9 IL13 IFNG
38 ovarian cancer 29.6 MMP9 MMP2 LCN2 IL2 IFNG HSPD1
39 bacterial infectious disease 29.6 TLR4 TLR2 TLR1 LCN2 IFNG HSPD1
40 meningitis 29.6 TLR4 TLR2 MMP9 IL2 IL13 IFNG
41 myocardial infarction 29.5 TLR4 TLR2 MPO MMP9 MMP2 LCN2
42 lung disease 29.5 TLR4 TLR2 MPO MMP9 IL13 IFNG
43 type 1 diabetes mellitus 29.4 TLR4 IL2 IFNG HSPD1 CST3 CRP
44 autoimmune disease 29.2 MPO MMP9 IL2 IL13 IFNG HSPD1
45 colorectal cancer 28.8 TLR4 TLR2 TLR1 MPO MMP9 MMP2
46 fitz-hugh-curtis syndrome 11.3
47 endometritis 11.2
48 benign multicystic peritoneal mesothelioma 11.1
49 ectopic pregnancy 10.9
50 heart valve disease 10.9

Comorbidity relations with Pelvic Inflammatory Disease via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Pelvic Inflammatory Disease:



Diseases related to Pelvic Inflammatory Disease

Symptoms & Phenotypes for Pelvic Inflammatory Disease

UMLS symptoms related to Pelvic Inflammatory Disease:


fever, pruritus, pelvic pain

MGI Mouse Phenotypes related to Pelvic Inflammatory Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 CDH1 CRP CST3 CXCL12 HSPD1 IFNG
2 immune system MP:0005387 10.32 CCL2 CDH1 CHI3L1 CRP CTSB CXCL12
3 hematopoietic system MP:0005397 10.31 CHI3L1 CXCL12 HSPD1 IFNG IL13 IL2
4 cellular MP:0005384 10.29 CDH1 CHI3L1 CST3 CTSB CXCL12 HSPD1
5 homeostasis/metabolism MP:0005376 10.25 CDH1 CRP CST3 CTSB IFNG IL13
6 mortality/aging MP:0010768 10.2 CDH1 CST3 CTSB CXCL12 HSPD1 IFNG
7 digestive/alimentary MP:0005381 10.06 CDH1 CTSB IFNG IL13 IL2 MMP9
8 muscle MP:0005369 9.96 CST3 CXCL12 HSPD1 IFNG IL13 MMP2
9 neoplasm MP:0002006 9.81 CDH1 CST3 CTSB IFNG IL2 MMP2
10 reproductive system MP:0005389 9.7 CDH1 CST3 CXCL12 HSPD1 IFNG IL13
11 respiratory system MP:0005388 9.23 HSPD1 IFNG IL13 IL2 MMP2 MMP9

Drugs & Therapeutics for Pelvic Inflammatory Disease

Drugs for Pelvic Inflammatory Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
2
Metronidazole Approved Phase 4 443-48-1 4173
3
Ofloxacin Approved Phase 4 82419-36-1 4583
4
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
5 Cytochrome P-450 Enzyme Inhibitors Phase 4
6 Norgestimate, ethinyl estradiol drug combination Phase 4
7 Antitubercular Agents Phase 4
8 Anti-Infective Agents Phase 4
9 Anti-Bacterial Agents Phase 4
10 Antibiotics, Antitubercular Phase 4
11 Anti-Inflammatory Agents Phase 4
12
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
13
Azithromycin Approved Phase 3 83905-01-5 55185 447043
14
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
15
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
16
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
17
Polyestradiol phosphate Approved Phase 3 28014-46-2
18 Contraceptive Agents Phase 3
19 Estradiol 3-benzoate Phase 3
20 Contraceptives, Oral Phase 3
21 Estradiol 17 beta-cypionate Phase 3
22 Contraceptives, Oral, Combined Phase 3
23
Ertapenem Approved, Investigational Phase 2 153832-46-3 150610
24
Clavulanate Approved, Vet_approved Phase 2 58001-44-8 5280980
25
Ticarcillin Approved, Investigational, Vet_approved Phase 2 34787-01-4 36921
26
Doxycycline Approved, Investigational, Vet_approved Phase 1, Phase 2 564-25-0 54671203
27
Nitrous oxide Approved, Vet_approved Phase 1, Phase 2 10024-97-2 948
28 beta-Lactamase Inhibitors Phase 2
29 Antiparasitic Agents Phase 1, Phase 2
30 Antiprotozoal Agents Phase 1, Phase 2
31 Antimalarials Phase 1, Phase 2
32 Pharmaceutical Solutions Phase 1
33
Iron Approved 7439-89-6 23925 29936
34
Curcumin Approved, Experimental, Investigational 458-37-7 969516
35 Protective Agents
36 Trace Elements
37 Antioxidants
38 Vitamins
39 Omega 3 Fatty Acid
40 Micronutrients
41 Nutrients
42 Analgesics
43 Analgesics, Non-Narcotic
44 Anti-Inflammatory Agents, Non-Steroidal
45 Antirheumatic Agents

Interventional clinical trials:

(show all 33)
# Name Status NCT ID Phase Drugs
1 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Unknown status NCT03391440 Phase 4 morinidazole
2 Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials Completed NCT01799356 Phase 4 Moxifloxacin;Ofloxacin;Metronidazole
3 Phase 4 Study of Azitromicin in the Treatment of PID Completed NCT01241110 Phase 4 Ofloxacin group A, Azitromycin group B;azitromycin
4 A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome):a Randomized, Double Blind, Parallel Control of Positive Drugs, Multi-center Clinical Study Not yet recruiting NCT04031664 Phase 4 Qianjin Capsule of Gynaecology
5 A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation):a Randomized, Double Blind, Parallel Control of Positive Drugs,Multi-center Clinical Study Not yet recruiting NCT04035785 Phase 4 Kangfu Anti-inflammatory Suppository
6 A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone Completed NCT01473836 Phase 3 Metronidazole;Ceftriaxone sodium
7 A Prospective, Randomized, Double Dummy, Double Blind, Multi-center Multinational Trial Comparing the Efficacy and Safety of Moxifloxacin 400 mg PO QD 24 Hours for 14 Days to That of Levofloxacin 500 mg PO QD 24 Hours Plus Metronidazole 500 mg BID for 14 Days in Subjects With an Uncomplicated Pelvic Inflammatory Disease (PID). Moxifloxacin, Metronidazole, and Levofloxacin in Asia (MONALISA Study) Completed NCT00453349 Phase 3 Moxifloxacin (Avelox, BAY12-8039);Levofloxacin & Metronidazole
8 Prospective, Randomized, Double-blind, Multicenter, Multinational Study Comparing Efficacy and Safety of Moxifloxacin 400 mg po od for 14 Days With Ofloxacin 400 mg po Bid Plus Metronidazole 500 mg po Bid for 14 Days in Patients With Uncomplicated Pelvic Inflammatory Disease (PID) Completed NCT00683865 Phase 3 Ofloxacin;Avelox (Moxifloxacin, BAY12-8039)
9 A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Pelvic Inflammatory Disease (PID) Requiring Initial Intravenous Therapy Completed NCT00871494 Phase 3 Azithromycin
10 Clinical Promotion Research of Complex Treatment With TCM to Diagnosis and Treatment on Different Syndrome Types of Pelvic Inflammatory Disease Sequelae Unknown status NCT02972151 Phase 2 Comprehensive treatment of TCM
11 The Clinical Effect of Fuke Qianjin Capsule on Chronic Pelvic Pain Caused by Pelvic Inflammation Unknown status NCT03251560 Phase 2 Fuke Qianjin capsule;Placebo oral capsule
12 The Importance of Anti-anaerobic Therapy for Acute PID Completed NCT01160640 Phase 2 Ceftriaxone;Doxycycline;Metronidazole;Placebo Oral Capsule
13 A Prospective, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Ertapenem Sodium ( MK0826) Versus Ticarcillin/Clavulanate in the Treatment of Hospital-Acquired Pneumonia, Complicated Intra-Abdominal Infections, and Acute Pelvic Infections in Pediatric Patients Completed NCT00092170 Phase 2 MK0826, ertapenem sodium;Comparator: Ticarcillin/Clavulanate
14 A Randomized, Double-blind, Positive-Controlled Study to Evaluate the Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases Not yet recruiting NCT04723069 Phase 1, Phase 2 Fuke Qianjin capsule;metronidazole tablets + doxycycline hyclate tablets
15 Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of Increasing Single Oral Doses of BAY1834845 Including Relative Bioavailability of a Liquid Versus a Solid Dosage in Healthy Male Volunteers Completed NCT03054402 Phase 1 BAY1834845;Placebo
16 Drug Use Investigation Of Azithromycin Iv Completed NCT01671280 Azithromycin IV
17 Zithromac Iv Special Investigation For Legionella Infection. Completed NCT01784770 Azithromycin IV
18 Improving Primary Care Follow-up for Adolescents With PID: A Randomized Controlled Trial Using Text Message Reminders Completed NCT01299259
19 Characterization of Novel Organisms in the Genital Tract of Women With PID and Determination of Their Association With Endometritis. Completed NCT01236131
20 Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease Completed NCT00115388
21 Technology Enhanced Community Health Nursing (TECH-N) to Prevent Recurrent Sexually Transmitted Infections After Pelvic Inflammatory Disease Completed NCT01640379
22 Rate of Pelvic Inflammatory Disease and Tubo-ovarian Abscess at SMH Completed NCT00783419
23 To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy Completed NCT01842100 Universal antibiotic prophylaxis
24 Randomized Trial of Laparoscopic Versus Abdominal Hysterectomy for Benign Indications and Impact on Surgical Success Completed NCT01793584
25 MOCHI: A Randomized Controlled Trial of Mindfulness as a Treatment for Chronic Pelvic Pain in Active Duty Women Completed NCT04104542
26 Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID Recruiting NCT03828994
27 Effect of Prophylactic Antibiotics for Hysterosalpingography on Post Procedure Morbidity Recruiting NCT04234945 Doxycycline Capsule;Multivitamins W/Iron Tab
28 Prospective Data Collection of Patients With Pelvic Inflammatory Disease Recruiting NCT02567812
29 A Comparison of Acute Toxicities Between Patients Treated With Protons or Intensity-Modulated Radiation Therapy for Post-Operative Treatment of Endometrial or Cervical Cancers Recruiting NCT04567771 Early Phase 1
30 Efficacy of Resistive Capacitive Monopolar Radiofrequency in the Physiotherapeutic Treatment of Chronic Pelvic Pain: Randomized Clinical Trial. Recruiting NCT03797911
31 Effect of an Anti-inflammatory Diet on the Nutritional Status and Cytokine Expression of Patients With Locally Advanced Cervical Cancer: A Randomized Clinical Trial Recruiting NCT03994055
32 Enriched Environments: a Multi-level Integrative Medicine Intervention for Endometriosis Recruiting NCT04179149
33 Curcumin Supplementation for Gynecological Diseases Including Pelvic Inflammatory Disease Endometritis, Endometriosis: A Pilot Study Recruiting NCT03016039

Search NIH Clinical Center for Pelvic Inflammatory Disease

Cochrane evidence based reviews: pelvic inflammatory disease

Genetic Tests for Pelvic Inflammatory Disease

Anatomical Context for Pelvic Inflammatory Disease

MalaCards organs/tissues related to Pelvic Inflammatory Disease:

40
Uterus, Breast, Ovary, Appendix, Neutrophil, Cervix, Colon

Publications for Pelvic Inflammatory Disease

Articles related to Pelvic Inflammatory Disease:

(show top 50) (show all 3992)
# Title Authors PMID Year
1
Guizhi Fuling wan for chronic pelvic inflammatory disease protocol: A protocol for systematic review and meta analysis. 61 42
33371080 2020
2
Efficacy and safety evaluation of acupuncture therapy for patients with salpingitis in IVF-ET: A protocol of systematic review and meta-analysis. 42
33466144 2021
3
THE ROLE OF SECRETING FUNCTION OF DECIDUA IN THE DEVELOPMENT OF COMPLICATIONS OF GESTATION PROCESS IN PREGNANT WOMEN WITH A PAST HISTORY OF CHRONIC ENDOMETRITIS. 42
33454676 2020
4
Chlamydia pneumoniae as a respiratory pathogen. 61 54
11861211 2002
5
Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat-shock protein in women with pelvic inflammatory disease. 61 54
9498452 1998
6
Inpatient treatment for uncomplicated and complicated acute pelvic inflammatory disease: ampicillin/sulbactam vs. Cefoxitin. 61 54
18475331 1993
7
Differential human serologic response to two 60,000 molecular weight Chlamydia trachomatis antigens. 54 61
2205652 1990
8
Ainsliaea fragrans champ. Extract prevents cervicitis in BALB/c mice and regulates MyD88-NF-κB signaling pathway in MALP-2-stimulated RAW264.7 cells. 61
33309583 2021
9
Inflammation calls for more: Severe pelvic inflammatory disease with or without endometriosis. Outcomes on 311 laparoscopically treated women. 61
32433940 2021
10
Immunopathogenesis of genital Chlamydia infection: insights from mouse models. 61
33538819 2021
11
Is primary dysmenorrhea a precursor of future endometriosis development? 61
33569996 2021
12
[Fitz-Hugh-Curtis syndrome can give pain under the right upper quadrant]. 61
33570027 2021
13
Anti-inflammatory effect of traditional Chinese medicine preparation Penyanling on pelvic inflammatory disease. 61
32979412 2021
14
A novel case of bilateral tubo-ovarian abscesses attributed to Ruminococcus gnavus without gastrointestinal involvement. 61
33271361 2021
15
A chlamydia education and training program for general practice nurses: reporting the effect on chlamydia testing uptake. 61
33526167 2021
16
Sexually Transmitted Infection Diagnoses and Access to a Sexual Health Service Before and After the National Lockdown for COVID-19 in Melbourne, Australia. 61
33506064 2021
17
The effects of human immunodeficiency virus, human papillomavirus, herpes simplex virus-1 and -2, human herpesvirus-6 and -8, cytomegalovirus, and hepatitis B and C virus on female fertility and pregnancy. 61
32726192 2021
18
Association between pelvic inflammatory disease and subsequent salpingectomy on the risk for ovarian cancer. 61
33418235 2021
19
Development of Pelvic Inflammatory Disease after Ectopic Removal. 61
33531793 2021
20
Case of a chronic ectopic pregnancy misdiagnosed as pelvic inflammatory disease. 61
33431533 2021
21
Study of Ectopic Pregnancy at Tertiary Care Hospital in Province 1 of Nepal. 61
33510513 2021
22
[Acupuncture combined with western medication on chronic pelvic pain after pelvic inflammatory disease: a multi-center randomized controlled trial]. 61
33559439 2021
23
[Update of Chlamydia trachomatis infection]. 61
33434747 2021
24
The Estimated Lifetime Medical Cost of Chlamydia, Gonorrhea, and Trichomoniasis in the United States, 2018. 61
33492090 2021
25
Trends and predictors of the use of unskilled birth attendants among Ethiopian mothers from 2000 to 2016. 61
33571781 2021
26
Acupuncture for chronic pelvic pain in patients with SPID: A protocol for systematic review and meta-analysis. 61
33530191 2021
27
Teaching the Evaluation of Female Pelvic Pain: A Hands-On Simulation to Reinforce Exam Skills and Introduce Transvaginal Ultrasound. 61
33511274 2021
28
The Diagnostic Value of Hysterosalpingography and Hysterolaparoscopy for Evaluating Uterine Cavity and Tubal Patency in Infertile Patients. 61
33569257 2021
29
New best practice guidance for general practice to reduce chlamydia-associated reproductive complications in women. 61
33543164 2021
30
The Herba Patriniae (Caprifoliaceae): A review on traditional uses, phytochemistry, pharmacology and quality control. 61
32846192 2021
31
Seroprevalence of Chlamydia trachomatis among female adults in the United States: The National Health and Nutrition Examination Surveys. 61
33367598 2020
32
Chlamydia-Specific IgA Secretion in the Female Reproductive Tract Induced via Per-Oral Immunization Confers Protection against Primary Chlamydia Challenge. 61
33139380 2020
33
Primary and secondary infertility in Africa: systematic review with meta-analysis. 61
33292584 2020
34
Pregnancy outcomes of the first thawing cycle in "freeze-all" strategy of infertility patients with fever during oocyte recruitment: a matched-pair study. 61
33278089 2020
35
Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. 61
33332296 2020
36
Clinical cure rate of pelvic inflammatory disease. Should ceftriaxone be part of the first line regimen? 61
33086939 2020
37
Mycoplasma genitalium as a Cause of Pelvic Inflammatory Disease. 61
32610147 2020
38
Evidence of human cytomegalovirus infection and expression of 5-lipoxygenase in borderline ovarian tumors. 61
33174621 2020
39
A Game Show-Based Curriculum for Teaching Principles of Reproductive Infectious Disease (GBS PRIDE Trial). 61
33140104 2020
40
Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial. 61
33188138 2020
41
Clearance of Mycoplasma genitalium and Trichomonas vaginalis Among Adolescents and Young Adults With Pelvic Inflammatory Disease: Results From the Tech-N Study. 61
32569258 2020
42
A Genital Infection-Attenuated Chlamydia muridarum Mutant Infects the Gastrointestinal Tract and Protects against Genital Tract Challenge. 61
33144378 2020
43
Alternative conformation of the C-domain of the P140 protein from Mycoplasma genitalium. 61
33135669 2020
44
Prevalence and incidence of Mycoplasma genitalium in a cohort of HIV-infected and HIV-uninfected pregnant women in Cape Town, South Africa. 61
31932358 2020
45
A Framework Proposal for Quality and Safety Measurement in Gynecologic Emergency Care. 61
33030878 2020
46
Evaluation of hysterosalpingographic findings among patients presenting with infertility. 61
33100842 2020
47
Epidemiologic and Clinical Characteristics of Tubo-Ovarian Abscess, Hydrosalpinx, Pyosalpinx, and Oophoritis in Emergency Department Patients. 61
33376658 2020
48
Impact of early surgical management on tubo-ovarian abscesses. 61
33249968 2020
49
Tubo-ovarian abscess in postmenopausal women: A systematic review. 61
32413520 2020
50
The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions. 61
33114134 2020

Variations for Pelvic Inflammatory Disease

Expression for Pelvic Inflammatory Disease

Search GEO for disease gene expression data for Pelvic Inflammatory Disease.

Pathways for Pelvic Inflammatory Disease

Pathways related to Pelvic Inflammatory Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.41 TLR6 TLR4 TLR2 TLR1 TIRAP IL2
2
Show member pathways
13.36 MMP9 MMP2 LCN2 IL2 IL13 IFNG
3
Show member pathways
13.17 TLR6 TLR4 TLR2 TLR1 TIRAP MPO
4
Show member pathways
13 TLR6 TLR4 TLR2 TLR1 TIRAP MMP9
5
Show member pathways
12.87 IL2 IL13 IFNG HSPD1 CXCL12 CTSB
6 12.85 MMP9 MMP2 IL2 IL13 IFNG CXCL12
7
Show member pathways
12.82 TLR4 TLR2 IL2 IFNG CCL2
8
Show member pathways
12.73 TLR6 TLR4 TLR2 TLR1 TIRAP
9
Show member pathways
12.71 TLR6 TLR4 TLR2 TLR1 IL2 CXCL12
10
Show member pathways
12.62 TLR4 TLR2 TIRAP IL2 IFNG
11
Show member pathways
12.61 TLR4 TLR2 IL2 IL13 IFNG
12
Show member pathways
12.6 MPO MMP2 IL2 IFNG CCL2
13
Show member pathways
12.6 TLR6 TLR4 TLR2 TLR1 TIRAP
14 12.52 TLR6 TLR2 TLR1 MPO IL2 IFNG
15
Show member pathways
12.5 TLR6 TLR4 TLR2 TLR1 TIRAP
16
Show member pathways
12.43 TLR6 TLR4 TLR2 TLR1 TIRAP
17
Show member pathways
12.41 IL2 IL13 IFNG CXCL12
18
Show member pathways
12.35 MPO IL2 IFNG CRP CCL2
19
Show member pathways
12.35 TLR2 MMP9 LCN2 IL13 IFNG CCL2
20 12.31 TLR4 TLR2 MMP9 MMP2
21
Show member pathways
12.28 TLR6 TLR4 TLR2 TLR1 TIRAP
22 12.17 TLR6 TLR4 TLR2 TLR1 TIRAP IFNG
23 12.16 TLR6 TLR4 TLR2 MPO
24 12.11 MMP9 MMP2 IFNG CCL2
25
Show member pathways
12.08 TLR6 TLR4 TLR2 TLR1 TIRAP IFNG
26 12.03 TLR4 MMP9 IL2 IFNG CCL2
27 12 MMP9 MMP2 LCN2 IL13 CCL2
28
Show member pathways
12 TLR6 TLR4 TLR2 TLR1 IL2 IL13
29 11.88 TLR4 TLR2 IFNG CXCL12 CCL2
30 11.86 TLR6 TLR4 TLR2 TLR1
31
Show member pathways
11.85 TLR6 TLR4 TLR2 TLR1 IFNG
32 11.84 MMP9 MMP2 CCL2
33 11.8 IL2 IL13 IFNG
34 11.79 IL2 IL13 IFNG
35 11.78 MMP9 MMP2 CDH1
36 11.78 TLR6 TLR4 TLR2 TLR1 MMP9 MMP2
37 11.75 IL2 IFNG CDH1
38 11.74 MMP9 MMP2 CDH1
39
Show member pathways
11.7 MMP9 MMP2 IL2 IFNG
40 11.69 TIRAP MMP9 MMP2
41 11.69 MMP9 MMP2 IL13 CCL2
42 11.62 TLR4 TLR2 HSPD1
43
Show member pathways
11.61 TLR6 TLR4 TLR2 TLR1 IL2 IFNG
44 11.58 TLR4 TLR2 IFNG CCL2
45 11.57 MMP2 IL2 IFNG
46 11.55 TLR4 TLR2 IFNG CCL2
47 11.54 MPO MMP9 MMP2
48 11.52 IL2 IL13 IFNG
49 11.36 MMP9 MMP2 CCL2
50 11.33 TLR4 MMP9 MMP2 CCL2

GO Terms for Pelvic Inflammatory Disease

Cellular components related to Pelvic Inflammatory Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 MPO MMP9 LCN2 HSPD1 CXCL12 CTSB
2 extracellular region GO:0005576 9.8 MPO MMP9 MMP2 LCN2 IL2 IL13
3 membrane raft GO:0045121 9.71 TLR6 TLR2 TLR1 HSPD1
4 phagocytic vesicle membrane GO:0030670 9.54 TLR6 TLR2 TLR1
5 extracellular space GO:0005615 9.47 MPO MMP9 MMP2 LCN2 IL2 IL13
6 lipopolysaccharide receptor complex GO:0046696 9.26 TLR4 HSPD1
7 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 9.16 TLR2 TLR1

Biological processes related to Pelvic Inflammatory Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.19 TLR6 TLR4 TLR2 TLR1 TIRAP LCN2
2 innate immune response GO:0045087 10.17 TLR6 TLR4 TLR2 TLR1 TIRAP LCN2
3 positive regulation of gene expression GO:0010628 10.14 TLR6 TLR4 TLR2 LCN2 IL13 IFNG
4 neutrophil degranulation GO:0043312 10.12 TLR2 MPO MMP9 LCN2 CTSB CST3
5 cytokine-mediated signaling pathway GO:0019221 10.08 MMP9 MMP2 LCN2 IL2 IL13 CCL2
6 defense response to bacterium GO:0042742 10.03 TLR6 TLR4 MPO LCN2
7 immune response GO:0006955 10.02 TLR6 TLR4 TLR2 TLR1 IL2 IL13
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 TLR4 TIRAP CHI3L1 CCL2
9 response to hypoxia GO:0001666 9.99 TLR2 MMP2 HSPD1 CXCL12
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TLR6 TLR4 TLR2 TIRAP
11 defense response GO:0006952 9.99 TLR1 MPO CXCL12 CST3
12 response to lipopolysaccharide GO:0032496 9.99 TLR4 TLR2 TIRAP MPO IL13 HSPD1
13 positive regulation of inflammatory response GO:0050729 9.93 TLR4 TLR2 IL2 IFNG HSPD1
14 response to mechanical stimulus GO:0009612 9.92 MPO IL13 CXCL12 CHI3L1
15 positive regulation of tumor necrosis factor production GO:0032760 9.92 TLR4 TLR2 TLR1 TIRAP IFNG
16 positive regulation of interleukin-8 production GO:0032757 9.91 TLR4 TLR2 TLR1 TIRAP
17 cellular response to interleukin-1 GO:0071347 9.9 LCN2 CHI3L1 CCL2
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IL2 IL13 IFNG
19 positive regulation of interferon-gamma production GO:0032729 9.88 TLR4 IL2 HSPD1
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TLR6 TLR4 IFNG
21 collagen catabolic process GO:0030574 9.86 MMP9 MMP2 CTSB
22 positive regulation of B cell proliferation GO:0030890 9.86 TLR4 TIRAP IL2 IL13
23 positive regulation of chemokine production GO:0032722 9.85 TLR4 TLR2 IFNG
24 positive regulation of interleukin-10 production GO:0032733 9.85 TLR4 TLR2 IL13 HSPD1
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TLR4 TLR2 CCL2
26 toll-like receptor signaling pathway GO:0002224 9.83 TLR6 TLR4 TLR2 TLR1 CTSB
27 activation of NF-kappaB-inducing kinase activity GO:0007250 9.81 TLR6 TIRAP CHI3L1
28 inflammatory response GO:0006954 9.81 TLR6 TLR4 TLR2 TLR1 TIRAP IL13
29 positive regulation of interleukin-12 production GO:0032735 9.8 TLR4 TLR2 TIRAP IFNG HSPD1
30 macrophage activation GO:0042116 9.79 TLR4 TLR1 IL13
31 cell activation GO:0001775 9.78 TLR6 TLR2 TLR1
32 positive regulation of macrophage activation GO:0043032 9.78 TLR6 TLR4 IL13 HSPD1
33 cellular response to lipoteichoic acid GO:0071223 9.76 TLR4 TLR2 TIRAP
34 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.76 TLR4 TLR2 IFNG CCL2
35 regulation of cytokine secretion GO:0050707 9.74 TLR6 TLR2 TLR1
36 cellular response to oxidised low-density lipoprotein particle stimulus GO:0140052 9.72 TLR6 TLR4
37 I-kappaB phosphorylation GO:0007252 9.72 TLR4 TLR2
38 cellular response to UV-A GO:0071492 9.72 MMP9 MMP2
39 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 TLR4 IFNG
40 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.71 TLR4 TIRAP
41 positive regulation of NLRP3 inflammasome complex assembly GO:1900227 9.71 TLR6 TLR4
42 positive regulation of NMDA glutamate receptor activity GO:1904783 9.7 IFNG CCL2
43 positive regulation of toll-like receptor 2 signaling pathway GO:0034137 9.7 TLR1 TIRAP
44 interleukin-1 beta production GO:0032611 9.7 TLR6 TLR4
45 cellular response to diacyl bacterial lipopeptide GO:0071726 9.7 TLR6 TLR2
46 positive regulation of oxidative stress-induced neuron death GO:1903223 9.68 TLR6 TLR4
47 toll-like receptor TLR6:TLR2 signaling pathway GO:0038124 9.68 TLR6 TLR2
48 toll-like receptor TLR1:TLR2 signaling pathway GO:0038123 9.67 TLR2 TLR1
49 positive regulation of matrix metallopeptidase secretion GO:1904466 9.67 TLR4 TLR2
50 response to bacterial lipoprotein GO:0032493 9.67 TLR6 TLR2 TLR1

Molecular functions related to Pelvic Inflammatory Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.43 TLR6 TLR4 TLR2 TLR1 TIRAP MPO
2 identical protein binding GO:0042802 10.02 TLR6 TLR4 TLR2 TLR1 TIRAP MMP9
3 transmembrane signaling receptor activity GO:0004888 9.81 TLR6 TLR4 TLR2 TLR1
4 signaling receptor activity GO:0038023 9.8 TLR6 TLR4 TLR2 TLR1
5 cytokine activity GO:0005125 9.8 IL2 IL13 IFNG CXCL12 CCL2
6 amyloid-beta binding GO:0001540 9.67 TLR6 TLR4 TLR2 CST3
7 lipopolysaccharide binding GO:0001530 9.63 TLR4 TLR2 HSPD1
8 lipopolysaccharide receptor activity GO:0001875 9.48 TLR4 TLR2
9 lipopeptide binding GO:0071723 9.43 TLR6 TLR2 TLR1
10 Toll-like receptor 2 binding GO:0035663 9.33 TLR6 TLR1 TIRAP
11 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.26 TLR6 TLR4 TLR2 TLR1
12 NAD(P)+ nucleosidase activity GO:0050135 8.92 TLR6 TLR4 TLR2 TLR1

Sources for Pelvic Inflammatory Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....